1. Scrip
  2. >>Business

Will The Dark Tunnel For Korean Biopharmas End In 2023?

Eyes On Lung Cancer, Alzheimer’s Segment

 
• By Jung Won Shin

Scrip wraps up major R&D and corporate developments for Korean biopharmas in 2022 and outlines what lies ahead for them in the new year.

Man walk through crystal corridor
Korean Firms See Decline In Financing, Licensing Deals In 2022 • Source: Shutterstock

Korean biopharmas have walked through a tunnel of financing drought and feeble licensing deals in 2022. Although there has been certain positive R&D progress, the overall industry sentiment, especially for bioventures, has been gloomy amid cost-cutting efforts.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.